1
|
Li J, Ma R, Lv JL, Ren YS, Tan YJ, Wang HM, Wang ZE, Wang BS, Yu JN, Wang YL, Tian J, Zheng QS. Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells. Phytomedicine 2024; 127:155440. [PMID: 38452691 DOI: 10.1016/j.phymed.2024.155440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 01/22/2024] [Accepted: 02/08/2024] [Indexed: 03/09/2024]
Abstract
BACKGROUND The high metastasis and mortality rates of head and neck squamous cell carcinoma (HNSCC) urgently require new treatment targets and drugs. A steroidal component of ChanSu, telocinobufagin (TBG), was verified to have anti-cancer effects in various tumors, but its activity and mechanism in anti-HNSCC were still unknown. PURPOSE This study tried to demonstrate the anti-tumor effect of TBG on HNSCC and verify its potential mechanism. METHODS The effect of TBG on cell proliferation and metastasis were performed and the TBG changed genes were detected by RNA-seq analysis in HNSCC cells. The GSEA and PPI analysis were used to identify the pathways targeted for TBG-regulated genes. Meanwhile, the mechanism of TBG on anti-proliferative and anti-metastasis were investigated in vitro and in vivo. RESULTS The in vitro and in vivo experiments confirmed that TBG has favorable anti-tumor effects by induced G2/M phase arrest and suppressed metastasis in HNSCC cells. Further RNA-seq analysis demonstrated the genes regulated by TBG were enriched at the G2/M checkpoint and PLK1 signaling pathway. Then, the bioinformatic analysis of clinical data found that high expressed PLK1 were closely associated with poor overall survival in HNSCC patients. Furthermore, PLK1 directly and indirectly modulated G2/M phase and metastasis (by regulated CTCF) in HNSCC cells, simultaneously. TBG significantly inhibited the protein levels of PLK1 in both phosphorylated and non-phosphorylated forms and then, in one way, inactivated PLK1 failed to activate G2/M phase-related proteins (including CDK1, CDC25c, and cyclin B1). In another way, be inhibited PLK1 unable promote the nuclear translocation of CTCF and thus suppressed HNSC cell metastasis. In contrast, the anti-proliferative and anti-metastasis effects of TBG on HNSCC cell were vanished when cells high-expressed PLK1. CONCLUSION The present study verified that PLK1 mediated TBG induced anti-tumor effect by modulated G2/M phase and metastasis in HNSCC cells.
Collapse
Affiliation(s)
- Jie Li
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China
| | - Ru Ma
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China; Department of Oral and Maxillofacial Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264003, China
| | - Jun-Lin Lv
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China
| | - Yu-Shan Ren
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China; Department of Immunology, Medicine & Pharmacy Research Center, Binzhou Medical University, Yantai 264003, China
| | - Yu-Jun Tan
- School of Life Science, Jiangsu Normal University, Xuzhou 221116, China; State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., Ltd, Linyi, 276000, China
| | - Hao-Mai Wang
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China
| | - Zhui-En Wang
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China
| | - Bin-Sheng Wang
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China
| | - Jia-Ning Yu
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China; Department of Thyroid & Breast Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264003, China
| | - Yu-Liang Wang
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China; Department of Oral and Maxillofacial Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264003, China.
| | - Jun Tian
- School of Life Science, Jiangsu Normal University, Xuzhou 221116, China.
| | - Qiu-Sheng Zheng
- School of Traditional Chinese Medicine, Binzhou Medical University, Yantai 264003, China.
| |
Collapse
|
2
|
Ma X, Xu W, Jin X, Mu H, Wang Z, Hua Y, Cai Z, Zhang T. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway. Eur J Pharmacol 2023; 942:175529. [PMID: 36690054 DOI: 10.1016/j.ejphar.2023.175529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 01/13/2023] [Accepted: 01/19/2023] [Indexed: 01/22/2023]
Abstract
Osteosarcoma is the most common primary bone malignancy in children and adolescents; it exhibits rapid growth and a high metastatic potential and may thus lead to relatively high mortality. The JAK2/STAT3 signaling pathway, which plays a critical role in the occurrence and development of osteosarcoma, is a potential target for the treatment of osteosarcoma. Here, we identified the natural product telocinobufagin (TCB), which is a component isolated from toad cake, as a potent candidate with anti-osteosarcoma effects. TCB inhibited osteosarcoma cell growth, migration, invasion and induced cancer cell apoptosis. Mechanistically, TCB specifically inhibited the JAK2/STAT3 signaling pathway. More importantly, TCB significantly suppressed tumor growth and metastasis in an osteosarcoma xenograft animal model. Moreover, TCB also showed strong inhibitory effects in other cancer types, such as lung cancer, liver cancer, colon cancer, breast cancer and gastric cancer. Hence, our study reveals TCB as a potent anti-osteosarcoma therapeutic agent that inhibits the JAK2/STAT3 signaling pathway.
Collapse
Affiliation(s)
- Xinglong Ma
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China; Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China
| | - Wenyuan Xu
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China
| | - Xinmeng Jin
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China
| | - Haoran Mu
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China
| | - Zhuoying Wang
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China
| | - Yingqi Hua
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China.
| | - Zhengdong Cai
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China.
| | - Tao Zhang
- Department of Orthopedics, Shanghai Bone Tumor Institution, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, PR China.
| |
Collapse
|
3
|
Feitosa GIMC, Carvalho IF, Coelho EBS, Monteiro MRB, Medeiros RL, Carvalho EDF, A Silva PT, Carvalho DMF, Uchoa DEA, Silveira ER, Santos CF, Nascimento NR, Carvalho MF, Cardi BA, Carvalho KM. Potent nonopioid antinociceptive activity of telocinobufagin in models of acute pain in mice. Pain Rep 2019; 4:e791. [PMID: 31984296 DOI: 10.1097/PR9.0000000000000791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 08/04/2019] [Accepted: 09/03/2019] [Indexed: 11/27/2022] Open
Abstract
Introduction: In recent decades, several researches have been conducted in search of new analgesics that do not present the side effects of opioids. In this context, animal venoms contain natural painkillers that have been used for the development of new analgesics. Objective: The aims of this study were to evaluate the antinociceptive effects of telocinobufagin (TCB), a bufadienolide isolated from Rhinella jimi venom, in murine acute pain models, and to verify the participation of the opioid system in these effects. Methods: TCB was purified from R. jimi venom by high-performance liquid chromatography, and its structure was confirmed by spectrometric techniques. TCB was administered intraperitoneally (i.p.) (0.062, 0.125, 0.25, 0.5, and 1 mg·kg−1) and orally (p.o.) (0.625, 1.125, 2.5, 5, and 10 mg·kg−1) in mice, which were then subjected to pain tests: acetic acid–induced writhing, formalin, tail-flick, and hot-plate. Involvement of the opioid system in TCB action was evaluated by naloxone i.p. injected (2.5 mg·kg−1) 20 minutes before TCB administration. In addition, the TCB action on the μ, δ, and κ opioid receptors was performed by radioligand binding assays. Results: In all the tests used, TCB showed dose-dependent antinociceptive activity with more than 90% inhibition of the nociceptive responses at the doses of 1 mg·kg−1 (i.p.) and 10 mg·kg−1 (p.o.). Naloxone did not alter the effect of TCB. In addition, TCB did not act on the μ, δ, and κ opioid receptors. Conclusion: The results suggest that TCB may represent a novel potential nonopioid therapeutic analgesic for treatment of acute pains.
Collapse
|
4
|
Dang YW, Lin P, Liu LM, He RQ, Zhang LJ, Peng ZG, Li XJ, Chen G. In silico analysis of the potential mechanism of telocinobufagin on breast cancer MCF-7 cells. Pathol Res Pract 2018; 214:631-643. [PMID: 29656985 DOI: 10.1016/j.prp.2018.03.029] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 03/20/2018] [Accepted: 03/31/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUNDS AND AIMS The extractives from a ChanSu, traditional Chinese medicine, have been discovered to possess anti-inflammatory and tumor-suppressing abilities. However, the molecular mechanism of telocinobufagin, a compound extracted from ChanSu, on breast cancer cells has not been clarified. The aim of this study is to investigate the underlying mechanism of telocinobufagin on breast cancer cells. METHODS AND MATERIALS The differentially expressed genes after telocinobufagin treatment on breast cancer cells were searched and downloaded from Gene Expression Omnibus (GEO), ArrayExpress and literatures. Bioinformatics tools were applied to further explore the potential mechanism of telocinobufagin in breast cancer using the Kyoto Encyclopedia of genes and genomes (KEGG) pathway, Gene ontology (GO) enrichment, panther, and protein-protein interaction analyses. To better comprehend the role of telocinobufagin in breast cancer, we also queried the Connectivity Map using the gene expression profiles of telocinobufagin treatment. RESULTS One GEO accession (GSE85871) provided 1251 differentially expressed genes after telocinobufagin treatment on MCF-7 cells. The pathway of neuroactive ligand-receptor interaction, cell adhesion molecules (CAMs), intestinal immune network for IgA production, hematopoietic cell lineage and calcium signaling pathway were the key pathways from KEGG analysis. IGF1 and KSR1, owning to higher protein levels in breast cancer tissues, IGF1 and KSR1 could be the hub genes related to telocinobufagin treatment. It was indicated that the molecular mechanism of telocinobufagin resembled that of fenspiride. CONCLUSIONS Telocinobufagin might regulate neuroactive ligand-receptor interaction pathway to exert its influences in breast cancer MCF-7 cells, and its molecular mechanism might share some similarities with fenspiride. This study only presented a comprehensive picture of the role of telocinobufagin in breast cancer MCF-7 cells using big data. However, more thorough and deeper researches are required to add to the validity of this study.
Collapse
Affiliation(s)
- Yi-Wu Dang
- Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Peng Lin
- The Ultrasonics Division of Radiology Department, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Li-Min Liu
- Department of Toxicology, College of Pharmacy, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Rong-Quan He
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Li-Jie Zhang
- The Ultrasonics Division of Radiology Department, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Zhi-Gang Peng
- Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Xiao-Jiao Li
- Department of PET-CT, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China
| | - Gang Chen
- Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China.
| |
Collapse
|
5
|
Wu SC, Fu BD, Shen HQ, Yi PF, Zhang LY, Lv S, Guo X, Xia F, Wu YL, Wei XB. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Int Immunopharmacol 2015; 25:353-62. [PMID: 25687199 DOI: 10.1016/j.intimp.2015.02.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2014] [Revised: 01/24/2015] [Accepted: 02/03/2015] [Indexed: 11/19/2022]
Abstract
Ideal potential vaccine adjuvants to stimulate a Th1 immune response are urgently needed to control intracellular infections in clinical applications. Telocinobufagin (TBG), an active component of Venenum bufonis, exhibits immunomodulatory activity. Therefore, we investigated whether TBG enhances the Th1 immune response to ovalbumin (OVA) and formalin-inactivated Salmonella typhimurium (FIST) in mice. TBG augmented serum OVA- and FIST-specific IgG and IgG2a and the production of IFNγ by antigen-restimulated splenocytes. TBG also dramatically enhanced splenocyte proliferative responses to concanavalin A, lipopolysaccharide, and OVA and substantially increased T-bet mRNA levels and the CD3(+)/CD3(+)CD4(+)/CD3(+)CD8(+) phenotype in splenocytes from OVA-immunized mice. In in vivo protection studies, TBG significantly decreased the bacterial burdens in the spleen and prolonged the survival time of FIST-immunized mice challenged with live S. typhimurium. In vivo neutralization of IFNγ with anti-IFNγ mAbs led to a significant reduction in FIST-specific IgG2a and IFNγ levels and in anti-Salmonella effect in TBG/FIST-immunized mice. In conclusion, these results suggest that TBG enhances a Th1 immune response to control intracellular infections.
Collapse
Affiliation(s)
- Shuai-Cheng Wu
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Ben-Dong Fu
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Hai-Qing Shen
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Peng-Fei Yi
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Li-Yan Zhang
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Shuang Lv
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Xun Guo
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Fang Xia
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Yong-Li Wu
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China
| | - Xu-Bin Wei
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, No. 5333, Xi'an Road, Changchun, Jilin 130062, PR China.
| |
Collapse
|